Cartesian Therapeutics (RNAC) said Monday the US Food and Drug Administration has agreed to the design of its phase 3 AURORA trial for Descartes-08, its mRNA cell therapy for myasthenia gravis, a chronic autoimmune disorder that causes muscle weakness.
The company said the randomized trial, expected to begin in H1, will compare Descartes-08 to a placebo in about 100 participants with acetylcholine receptor autoantibody-positive myasthenia gravis.
The primary endpoint will measure the percentage of patients with a three-point or greater improvement in myasthenia gravis activities of daily living scores after four months, Cartesian added.
Shares of the company were up 2.9% in recent Monday trading.
Price: 19.76, Change: +0.56, Percent Change: +2.89
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。